dextropropoxyphene   Click here for help

GtoPdb Ligand ID: 7593

Synonyms: (+)-alpha-propoxyphene | Darvon® | propoxyphene
Approved drug
dextropropoxyphene is an approved drug
Compound class: Synthetic organic
Comment: Dextropropoxyphene is principally an opioid analgesic. Chemically it is an optical isomer of levopropoxyphene (the (2R,3S) optical isomer with PubChem CID 200742); dextropropoxyphene being the (2S,3R) enantiomer. Marketing in Europe and the US has been discontinued due to concerns of fatal overdoses and heart arrhythmias.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 9
Topological polar surface area 29.54
Molecular weight 339.22
XLogP 4.37
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(=O)OC(c1ccccc1)(C(CN(C)C)C)Cc1ccccc1
Isomeric SMILES CCC(=O)O[C@](c1ccccc1)([C@@H](CN(C)C)C)Cc1ccccc1
InChI InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1
InChI Key XLMALTXPSGQGBX-GCJKJVERSA-N
No information available.
Summary of Clinical Use Click here for help
Used to treat mild pain. Although withdrawn from the US and European markets, other individual national approval agencies may still grant marketing authorisation for this drug. The majority of international brand names contain this drug in combination with paracetamol, some contain dextropropoxyphene and metamizole.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Dextropropoxyphene is a μ opioid receptor agonist. Activation of this receptor on central nervous system neurons inhibits intracellular adenylate cyclase. Downstream this leads to reduced calcium influx via membrane calcium channels, and increased potassium permeability by opening membrane potassium channels. This ultimately leads to hyperpolarization of the cell membrane potential and suppression of action potential transmission of ascending pain pathways. Experimental evidence also suggests that dextropropoxyphene can behave as a potent, noncompetitive α3β4 neuronal nicotinic acetylcholine receptor antagonist [1], and as a weak serotonin reuptake inhibitor.